Pancreatic Cancer Research

ResearcherUniversidad Complutense de MadridActive in the last 2 years

Andrés Jesús Muñoz Martín

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6977-8249; OpenAlex author ID A5042384932, A5104008293. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 17

  1. Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic re… Co-author DOI 10.1016/j.ctrv.2026.103174↗
  2. Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group. Co-author DOI 10.1016/j.pan.2026.08.008↗
  3. Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. First author DOI 10.1016/j.esmorw.2025.100116↗
  4. Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.1007/s12094-024-03467-8↗
  5. Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial. Co-author DOI 10.4251/wjgo.v16.i2.386↗
  6. Which events to consider in the study of venous thromboses in pancreatic cancer patients? Authors' reply. Last author DOI 10.1016/j.ejim.2023.01.013↗
  7. Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline". Co-author DOI 10.14701/ahbps.22-023↗
  8. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  9. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. Co-author DOI 10.14701/ahbps.2021.25.2.179↗
  10. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing… Co-author DOI 10.1186/s12885-020-07110-x↗
  11. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cance… Co-author DOI 10.1200/jco.18.00089↗
  12. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. Co-author DOI 10.1186/s12885-018-5101-3↗
  13. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. Co-author DOI 10.7150/jca.23716↗
  14. Pancreatic ductal adenocarcinoma: metastatic disease. Co-author DOI 10.1007/s12094-017-1690-6↗
  15. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2016.271↗
  16. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group pe… Co-author DOI 10.3892/ol.2016.4667↗
  17. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model. Co-author DOI 10.1007/s12094-014-1165-y↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Luis Cabezón‐Gutiérrez · 3 shared papers, 2024–2026 · strength 0.73
  2. Vilma Pacheco-Barcía · 3 shared papers, 2024–2026 · strength 0.73
  3. Alberto Carmona‐Bayonas · 3 shared papers, 2018–2026 · strength 0.49
  4. Javier Gallego-Plazas · 3 shared papers, 2018–2026 · strength 0.49
  5. Teresa Mercade Macarulla · 4 shared papers, 2018–2025 · strength 0.46
  6. M. Martín Jiménez · 3 shared papers, 2014–2024 · strength 0.38
  7. Roberto Pazo-Cid · 4 shared papers, 2016–2025 · strength 0.36
  8. Carmen Guillén‐Ponce · 3 shared papers, 2018–2026 · strength 0.36
  9. Álvaro Gregorio Morales Taboada · 2 shared papers, 2021–2022 · strength 0.33
  10. José Manuel Asencio · 2 shared papers, 2021–2022 · strength 0.33
  11. Beatriz Chacón-Ovejero · 1 shared paper, 2026 · strength 0.30
  12. Alfredo Carrato · 2 shared papers, 2018–2025 · strength 0.27
  13. Silvia García Adrián · 1 shared paper, 2023 · strength 0.26
  14. Joaquina Martínez-Galán · 3 shared papers, 2017–2019 · strength 0.25
  15. Manuel M. Hidalgo · 3 shared papers, 2017–2019 · strength 0.25
  16. Irene González Caraballo · 1 shared paper, 2024 · strength 0.24
  17. Ángela Lamarca · 1 shared paper, 2026 · strength 0.22
  18. Elena Brozos-Vázquez · 1 shared paper, 2026 · strength 0.22
  19. Sara Lonardi · 2 shared papers, 2020–2021 · strength 0.21
  20. Joel Randolph Hecht · 2 shared papers, 2020–2021 · strength 0.21
  21. Baek‐Yeol Ryoo · 2 shared papers, 2020–2021 · strength 0.21
  22. Johanna C. Bendell · 2 shared papers, 2020–2021 · strength 0.21
  23. Ismael Ghanem · 1 shared paper, 2025 · strength 0.18
  24. Florian Castet · 1 shared paper, 2025 · strength 0.18
  25. Berta Laquente · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.